Profit Over People: How Private Equity Transformed Autism Therapy into a $7 Billion Medicaid Industry

By Investigative Staff

The landscape of autism care in America has undergone a seismic shift, evolving from a clinical support system into a high-stakes, multi-billion-dollar corporate enterprise. A sweeping investigation by The 74 into 275 million records from the U.S. Department of Government Efficiency (DOGE) reveals that while federal authorities were busy conducting high-profile, politically charged raids on autism centers under the guise of combating "welfare fraud," a more systemic form of exploitation was occurring in plain sight.

Between 2019 and 2024, private equity firms—entities often shielded from public scrutiny—capitalized on the autism therapy industry to the tune of $7 billion in taxpayer-funded Medicaid payments. This explosive growth has not resulted in better outcomes for children; rather, it has prioritized a standardized, controversial behavior modification system over individualized, humane support.

The Main Facts: A System Primed for Exploitation

At the center of this controversy is Applied Behavior Analysis (ABA), a therapy model dating back to the 1960s that utilizes a system of rewards and punishments to "extinguish" specific behaviors. While pediatricians frequently prescribe ABA as the "gold standard" for autism, a growing chorus of autistic adults, researchers, and disability advocates argue the therapy is frequently ineffective and often psychologically traumatizing.

The 74 investigation found that Medicaid claims for the six most common autism therapy billing codes surged by 381% over six years, jumping from $400 million annually to nearly $2 billion. Private equity-backed providers, which operate with minimal transparency, are leading this billing surge. These firms typically acquire privately held clinics, implement aggressive growth strategies designed to extract short-term profits, and prioritize high-volume, standardized "treatments" that maximize billable hours rather than patient health.

A Chronology of Corporate Capture

The transformation of autism therapy into a corporate commodity did not happen overnight. It was the result of a deliberate convergence of lobbying, legislative shifts, and aggressive financial maneuvering.

• 2007: The Grassroots Catalyst: Following the advocacy of parents like Lorri Unumb, states began passing "Ryan’s Law," forcing private insurers to cover ABA. While intended to help families afford expensive therapy, these laws created a guaranteed revenue stream for providers.
• 2014: The Medicaid Mandate: The Obama administration clarified that the Affordable Care Act required Medicaid to cover autism treatment. This opened the floodgates for public funding, suddenly making the industry a target for institutional investors.
• 2015–2024: The PE Gold Rush: Private equity firms began a buying spree, acquiring 574 sites run by 147 providers. By 2019, large, multi-state chains dominated the landscape, leveraging their size to negotiate higher reimbursement rates from states.
• 2022–Present: The Regulatory Reckoning: Federal audits in both red and blue states began to expose the dark reality of this growth, documenting massive improper billing, lack of oversight, and the denial of educational rights to children kept in clinical settings instead of schools.

Supporting Data: The Cost of Corporate Dominance

The data provided by the DOGE dataset illustrates a clear correlation between private equity ownership and the escalation of Medicaid spending.

Of the 50 largest providers by Medicaid billing, 23 are (or were) owned by private equity. These firms billed $2 billion over the study period. Even more striking, the top 15 providers—11 of which are private equity-owned—accounted for over $1.5 billion in taxpayer funds.

The financial incentive structure is inherently flawed. ABA clinics often push for 40 hours of therapy per week—a schedule that is effectively a full-time job for a toddler. Ari Ne’Eman, a former director of the Autistic Self-Advocacy Network, notes that private equity didn’t corrupt the field so much as it exploited pre-existing, "tidy" financial arrangements that rewarded intensity over quality.

Furthermore, the human cost is quantifiable. A 2018 study of 460 autistic adults and caregivers found that nearly half of those who underwent ABA displayed symptoms of post-traumatic stress. More recent research from the University of Wisconsin-Madison and other institutions indicates that individuals who participated in ABA before age 18 are 30% more likely to require mental health hospitalization compared to those who did not.

Official Responses and the "Bad Actor" Defense

The industry’s response to these findings has been largely defensive. Lorri Unumb, now CEO of the Council of Autism Service Providers, maintains that "bad actors" exist in every profession and that thousands of ethical providers are making a difference.

However, the corporate structure of these firms makes accountability nearly impossible. When a private equity-owned chain like the Centers for Autism and Related Disorders (CARD) faced financial collapse, it was the clinics and the families that suffered, while the investment managers—who directed the strategies—remained shielded by the corporate veil.

Blackstone, which acquired CARD in 2018, stated in response to The 74 that it never made clinical decisions and that it attempted to manage a "perfect storm" of COVID-19-era lockdowns and labor shortages. Yet, former employees have described a corporate culture that prioritized younger children simply because they could be kept in the system longer, maximizing long-term billing potential.

The Implications: A Darker Path Forward

The implications of this corporate capture are profound, particularly as political discourse shifts toward the total deregulation of federal agencies.

1. The Erosion of Educational Rights

Federal audits in states like Colorado and Indiana have exposed a recurring scandal: children are being kept in clinical, non-academic environments for years, effectively being denied their right to an education. In some cases, children remained in therapy centers until age 16, with taxpayers footing bills exceeding $140,000 annually per child, while the centers failed to provide basic schooling.

2. The Failure of Oversight

When states attempt to regulate, they often fall into the trap of letting the industry police itself. Colorado’s recent attempt to license therapists resulted in a board dominated by industry insiders, ensuring that the "status quo" of ABA remains protected from the influence of autistic adults and mental health professionals who advocate for more modern, evidence-based supports.

3. A Return to "Cures"

The current political climate, led by figures like Robert F. Kennedy Jr., threatens to further regress progress. By prioritizing the search for disproven "cures" over research into improving the quality of life for autistic people, the government risks fueling the same eugenicist ideologies that influenced early figures like Ole Ivar Lovaas and Hans Asperger.

Conclusion: A Call for Systemic Change

The crisis in autism therapy is not merely a story of fraud; it is a story of how a vulnerable population has been turned into a profit engine for the financial sector. As long as private equity is permitted to prioritize high-volume billing over individualized care, the most vulnerable among us will continue to bear the cost.

For advocates, the path forward is clear: it requires joint liability for investment firms, a decoupling of profit from patient-care decisions, and a shift in focus from "extinguishing" autistic traits to providing the academic and social supports that allow autistic individuals to live with dignity. Without these structural reforms, the "industry" of autism therapy will continue to thrive, even as the children it claims to serve pay the ultimate price.